Pliant Therapeutics (PLRX) Operating Income (2019 - 2026)
Pliant Therapeutics (PLRX) reported Operating Income of -$21.8 million for Q1 2026, up 63.06% year-over-year from -$13.4 million in Q1 2025, and up 7.66% quarter-over-quarter from -$23.6 million in Q4 2025.
Pliant Therapeutics (PLRX) Operating Income (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Operating Income data on file, last reported at -$21.8 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$21.8 million, up 63.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$119.2 million (up 49.25% YoY), and the FY2025 annual result was -$156.4 million, up 31.52% from the prior year.
- Operating Income climbed to -$21.8 million in Q1 2026 per PLRX's latest filing, from -$23.6 million in the prior quarter.
- Over five years, Operating Income peaked at -$21.8 million in Q1 2026 and troughed at -$62.0 million in Q3 2024.
- A 5-year average of -$42.2 million and a median of -$45.6 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2026: Operating Income plunged 59.67% in 2023, then jumped 63.06% in 2026.
- A 5-year view of Operating Income shows it stood at -$37.4 million in 2022, then decreased by 25.77% to -$47.0 million in 2023, then dropped by 13.36% to -$53.3 million in 2024, then soared by 55.78% to -$23.6 million in 2025, then advanced by 7.66% to -$21.8 million in 2026.
- Business Quant data shows PLRX's Operating Income at -$21.8 million in Q1 2026, -$23.6 million in Q4 2025, and -$28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | -21.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.77 Mn |
| Dec 31, 2025 | -23.58 Mn |
| Sep 30, 2025 | -28.27 Mn |
| Jun 30, 2025 | -45.59 Mn |
| Mar 31, 2025 | -58.94 Mn |
| Dec 31, 2024 | -53.32 Mn |
| Sep 30, 2024 | -62.01 Mn |
| Jun 30, 2024 | -60.64 Mn |
| Mar 31, 2024 | -52.39 Mn |
| Dec 31, 2023 | -47.04 Mn |
| Sep 30, 2023 | -47.69 Mn |
| Jun 30, 2023 | -47.33 Mn |
| Mar 31, 2023 | -42.10 Mn |
| Dec 31, 2022 | -37.40 Mn |
| Sep 30, 2022 | -31.95 Mn |
| Jun 30, 2022 | -29.64 Mn |
| Mar 31, 2022 | -28.21 Mn |
| Dec 31, 2021 | -24.60 Mn |
| Sep 30, 2021 | -27.11 Mn |
| Jun 30, 2021 | -22.90 Mn |